The Technical Analyst
Rhythm Pharmaceuticals [RYTM]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Rhythm Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.55% $37.52
America/New_York / 19 apr 2024 @ 14:22
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 256.47 mill |
| EPS: | -3.20 |
| P/E: | -11.72 |
| Earnings Date: | Apr 30, 2024 |
| SharesOutstanding: | 60.14 mill |
| Avg Daily Volume: | 0.602 mill |
| RATING 2024-04-19 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -11.72 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.99x |
| Company: PE -11.72 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-24.79 (-166.08%) $-62.31 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 35.51 - 39.76 ( +/- 5.65%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-14 | Mazabraud Yann | Sell | 10 375 | Common Stock |
| 2024-04-14 | Mazabraud Yann | Sell | 10 375 | Restricted Stock Units |
| 2024-04-15 | Mazabraud Yann | Buy | 10 000 | Restricted Stock Units |
| 2024-04-15 | Mazabraud Yann | Buy | 8 905 | Restricted Stock Units |
| 2024-04-15 | Mazabraud Yann | Sell | 6 874 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 38.89 |
| Last 100 transactions |
| Buy: 1 143 191 | Sell: 502 628 |
Forecast:
16:00 - $37.52
Live Trading Signals (every 1 min)
Forecast
1: 14:31 - $37.59
Forecast 2: 15:21 - $37.59
Forecast 3: 16:00 - $37.52
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $37.52 (-1.55% ) |
| Volume | 0.198 mill |
| Avg. Vol. | 0.602 mill |
| % of Avg. Vol | 32.91 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RYTM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $47.73 | N/A | Active |
|---|
RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Latest Press Releases
2024-04-16 16:01:00 - Press Release
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Boston, april 16, 2024 (globe newswire) -- rhythm pharmaceuticals, inc. (nasdaq: rytm), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on april 11, 2024, the compensation committee of rhythm's board of directors granted inducement equity grants covering an aggregate of 31,220 shares of its common stock to eight new employees, consisting of inducement stock options to purchase an aggregate of 16,480 shares of common stock and inducement restricted stock units, or rsus, covering an aggregate of 14,740 shares of its common stock.
2024-04-01 08:00:00 - Press Release
Rhythm Pharmaceuticals Secures $150 Million In Convertible Preferred Stock Financing
-- proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 -- -- proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 --
2024-03-25 08:00:00 - Press Release
Rhythm Pharmaceuticals Announces First Patient Dosed In Phase 1 Trial Evaluating Rm-718, A Weekly Mc4r-specific Agonist
-- three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- rm-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation observed in preclinical studies --
2024-03-11 16:01:00 - Press Release
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Boston, march 11, 2024 (globe newswire) -- rhythm pharmaceuticals, inc. (nasdaq: rytm), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on march 6, 2024, the compensation committee of rhythm's board of directors granted inducement equity grants covering an aggregate of 13,780 shares of its common stock to three new employees, consisting of inducement stock options to purchase an aggregate of 9,180 shares of common stock and inducement restricted stock units, or rsus, covering an aggregate of 4,600 shares of its common stock.
2024-03-06 16:01:00 - Press Release
Rhythm Pharmaceuticals Announces Participation At Upcoming Investor Conferences
Boston, march 06, 2024 (globe newswire) -- rhythm pharmaceuticals, inc. (nasdaq: rytm), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the company will participate in two upcoming investor conferences.
Latest News
2024-03-28 09:33:14 - CNBC Television
Hennion & Walsh's Kevin Mahn on his top stock picks: CRWD, MSFT, LLY, RYTM
Kevin Mahn, Hennion & Walsh Asset Management president and CIO, joins 'Squawk Box' to discuss the latest market trends, why he believes AI isn't the only game in town for the markets, and more.
2024-03-06 16:01:00 - GlobeNewsWire
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Company will participate in two upcoming investor conferences.
2024-02-22 23:33:09 - Seeking Alpha
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2023 Earnings Call Transcript
2024-02-22 09:10:17 - Zacks Investment Research
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.70 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.75 per share a year ago.
2024-01-31 08:00:00 - GlobeNewsWire
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Company to participate in fireside chats at Guggenheim's 6th Annual Biotechnology Conference on Feb. 7 and TD Cowen 44th Annual Health Care Conference on March 5 Company to participate in fireside chats at Guggenheim's 6th Annual Biotechnology Conference on Feb. 7 and TD Cowen 44th Annual Health Care Conference on March 5
2024-01-16 07:01:35 - MarketBeat
2 biotechs with promising weight-loss drugs coming
Clinical weight-loss medications have been making headlines. GLP-1 drugs like Novo Nordisk A/S NYSE: NVO owned Ozempic and Wegovy and Eli Lilly and Co. NYSE: LLY owned Mounjaro and Zepbound continue to see demand outstrip supply.
2023-11-07 09:46:36 - Zacks Investment Research
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.76 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.79 per share a year ago.
2023-10-25 08:00:00 - GlobeNewsWire
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 7, 2023 to report its third quarter 2023 financial results and provide a corporate update.
2023-08-28 08:00:00 - GlobeNewsWire
Rhythm Pharmaceuticals to Present at Investor Conferences in September
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that Company management will present at three investor conferences in September:
2023-08-04 15:08:00 - Seeking Alpha
Rhythm Pharmaceuticals: A Virtual Monopoly In Orphan Obesity Disorders
Rhythm Pharmaceuticals, Inc. is focused on developing treatments for orphan obesity syndromes caused by defects in the MC4R pathway. Their product Imcivree is currently approved for treating Bardet Biedel syndrome, POMC, PCSK1, and LEPR deficiencies. Q2 2023 revenue more than doubled annually, and Rhythm Pharmaceuticals is conducting late-stage trials in additional orphan obesity indications.